Drug Resistance in Cancer: Molecular Evolution and Compensatory Proliferation

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Feb 25

PMID 26909596

Citations 35

Authors

Ran Friedman

Affiliations

Soon will be listed here.

Abstract

Targeted therapies have revolutionized cancer treatment. Unfortunately, their success is limited due to the development of drug resistance within the tumor, which is an evolutionary process. Understanding how drug resistance evolves is a prerequisite to a better success of targeted therapies. Resistance is usually explained as a response to evolutionary pressure imposed by treatment. Thus, evolutionary understanding can and should be used in the design and treatment of cancer. In this article, drug-resistance to targeted therapies is reviewed from an evolutionary standpoint. The concept of apoptosis-induced compensatory proliferation (AICP) is developed. It is shown that AICP helps to explain some of the phenomena that are observed experimentally in cancers. Finally, potential drug targets are suggested in light of AICP.

Citing Articles

Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis.

Yang J, Friedman R Biochem Biophys Rep. 2025; 41:101894.

PMID: 39896109 PMC: 11786753. DOI: 10.1016/j.bbrep.2024.101894.

The Spiral Model of Evolution: Stable Life Forms of Organisms and Unstable Life Forms of Cancers.

Kasperski A, Heng H Int J Mol Sci. 2024; 25(17).

PMID: 39273111 PMC: 11395208. DOI: 10.3390/ijms25179163.

Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells.

Tang M, Zhang Z, Wang P, Zhao F, Miao L, Wang Y Acta Pharm Sin B. 2024; 14(8):3457-3475.

PMID: 39220884 PMC: 11365446. DOI: 10.1016/j.apsb.2024.04.034.

An evolutionary differential game for regulating the role of monoclonal antibodies in treating signalling pathways in oesophageal cancer.

Alajmi M, Roy S R Soc Open Sci. 2024; 11(7):240347.

PMID: 39086820 PMC: 11289643. DOI: 10.1098/rsos.240347.

Modeling the Effect of Spatial Structure on Solid Tumor Evolution and Circulating Tumor DNA Composition.

Rachman T, Bartlett D, LaFramboise W, Wagner P, Schwartz R, Carja O Cancers (Basel). 2024; 16(5).

PMID: 38473206 PMC: 10930890. DOI: 10.3390/cancers16050844.

References

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Blagosklonny M . Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer. 2002; 2(3):221-5. DOI: 10.1038/nrc743. View

Roche-Lestienne C, Soenen-Cornu V, Lai J, Philippe N, Facon T, Fenaux P . Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002; 100(3):1014-8. DOI: 10.1182/blood.v100.3.1014. View

Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J . Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2(2):117-25. DOI: 10.1016/s1535-6108(02)00096-x. View

Muller M, Lahaye T, Hochhaus A . [Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells]. Dtsch Med Wochenschr. 2002; 127(42):2205-7. DOI: 10.1055/s-2002-34939. View

Glaser F, Pupko T, Paz I, Bell R, Martz E, Ben-Tal N . ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics. 2002; 19(1):163-4. DOI: 10.1093/bioinformatics/19.1.163. View

Hofmann W, Komor M, Wassmann B, Jones L, Gschaidmeier H, Hoelzer D . Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood. 2003; 102(2):659-61. DOI: 10.1182/blood-2002-06-1756. View

Blagosklonny M . Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; 5(1):13-7. DOI: 10.1016/s1535-6108(03)00336-2. View

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

10.

Hato T, Yamanouchi J, Tamura T, Hojo N, Niiya Y, Kohno M . Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. Int J Hematol. 2004; 80(1):62-6. DOI: 10.1532/ijh97.04033. View

11.

Ryoo H, Gorenc T, Steller H . Apoptotic cells can induce compensatory cell proliferation through the JNK and the Wingless signaling pathways. Dev Cell. 2004; 7(4):491-501. DOI: 10.1016/j.devcel.2004.08.019. View

12.

Sawyers C . Targeted cancer therapy. Nature. 2004; 432(7015):294-7. DOI: 10.1038/nature03095. View

13.

Blagosklonny M . Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ. 2005; 12(6):592-602. DOI: 10.1038/sj.cdd.4401610. View

14.

Ghobrial I, Witzig T, Adjei A . Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005; 55(3):178-94. DOI: 10.3322/canjclin.55.3.178. View

15.

Huff C, Matsui W, Smith B, Jones R . The paradox of response and survival in cancer therapeutics. Blood. 2005; 107(2):431-4. PMC: 1895602. DOI: 10.1182/blood-2005-06-2517. View

16.

Blagosklonny M . Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle. 2005; 4(12):1693-8. DOI: 10.4161/cc.4.12.2259. View

17.

Blagosklonny M . Target for cancer therapy: proliferating cells or stem cells. Leukemia. 2005; 20(3):385-91. DOI: 10.1038/sj.leu.2404075. View

18.

Wang T, Bhatt D, Topol E . Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2005; 27(6):647-54. DOI: 10.1093/eurheartj/ehi684. View

19.

Iwasa Y, Nowak M, Michor F . Evolution of resistance during clonal expansion. Genetics. 2006; 172(4):2557-66. PMC: 1456382. DOI: 10.1534/genetics.105.049791. View

20.

Li L, Neaves W . Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006; 66(9):4553-7. DOI: 10.1158/0008-5472.CAN-05-3986. View